Celltrion to commence interchangeability trials of Yuflyma® (biosimilar adalimumab)

Oct 5, 2022

Celltrion announced the commencement of Ph III clinical trials regarding Yuflyma® (biosimilar adalimumab) in Estonia.  This trial will run for 13 months and will be used to support Celltrion’s application for interchangeability in the US.  Yuflyma was approved in the EU in February 2021, and in Canada in December 2021.

Print Page Mail Article